Novo Nordisk to conduct trial of new obesity drug CagriSema in pediatric patients

On December 2, Novo Nordisk, the manufacturer of Wegovy, announced plans to investigate its new obesity medication, CagriSema, in children and teenagers struggling with excess weight, according to a U.S. clinical trial registry.

The upcoming late-stage study, starting in January, aims to recruit 460 participants aged eight and older across 97 centers worldwide, including locations in the United States, China, and Europe.

CagriSema is a combination therapy that pairs cagrilintide, a compound that imitates the pancreatic hormone amylin, with semaglutide, the primary component of Wegovy.

The trials primary focus will be on measuring changes in body weight from baseline over 68 weeks in participants randomly assigned to receive either CagriSema, cagrilintide alone, semaglutide alone, or a placebo.

While Novo Nordisk has positioned CagriSema as a more powerful follow-up to its successful Wegovy treatment, previous studies showed less weight reduction than anticipated, prompting a renewed late-stage trial launched in June.

Author: Maya Henderson